Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lung Neoplasms × Clindamycin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Tract Infections 1 Urinary Bladder Neoplasms 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Exanthema 1 Colorectal Neoplasms 1

Interventions

Carboplatin 171 Paclitaxel 129 Radiotherapy 119 Cisplatin 109 Docetaxel 91 Gemcitabine 81 Erlotinib Hydrochloride 79 Pemetrexed 78 Bevacizumab 56 Etoposide 41 pembrolizumab 35 Gefitinib 32 Vinorelbine 31 Topotecan 30 Surveys and Questionnaires 28 Irinotecan 28 Radiosurgery 21 Nivolumab 20 Drug Therapy 20 Magnetic Resonance Spectroscopy 18 Cetuximab 18 Early Intervention, Educational 17 Blood Specimen Collection 17 durvalumab 16 Surgical Procedures, Operative 16 Cyclophosphamide 16 Celecoxib 15 Ipilimumab 14 Immunohistochemistry 14 Filgrastim 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡